Browse

Rare disease drugmakers are watching the Trump administration closely as proposals emerge that could force lower prices for their specialty therapies. The companies are exploring strategies to miti…

Novartis chief executive Vas Narasimhan told reporters during the second quarter earnings call that the company’s recent agreements in China are motivated by scientific opportunities rather than a…